GENINCODE PLC (GENI) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the GENINCODE PLC full year results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the q and a tab situated in the right corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question received from the meeting itself. However, the company can review all the questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Matthew Wall, CEO. Good afternoon to you, sir. Good afternoon, Alessandro, and good afternoon, everyone. Welcome to the 2023 final results and business update. I'm here at the Cavendish Broker offices in the center of London with Paul, our CFO. And we're gonna walk through the results presentation from 2023. I decided that it'd be worthwhile moving with a little bit of pace. We've got a lot to cover. And for those who've had chance to read yesterday's r and s, there's quite a bit to get through. So I'm gonna move a little bit quick quicker through today's presentation so that towards the end, do we have a bit more time for q and a? But in in any event, we'll cover off the the headlines and and the key points. So moving on. I'll also move through some of these slides a little bit faster than I would normally. But just as a a headline, we are a predictive genetics bioinformatics company. We have a high amount of structured algorithms in the background around the way we calculate and risk score cardiovascular disease, and we're now obviously taking our products to market in Europe, The UK, and The US. And the rest of this presentation...